Skip to main content
رجوع
DSKYF logo

Daiichi Sankyo Company, Limited

جودة البيانات: 100%
DSKYF
OTC Healthcare Drug Manufacturers - General
KWD 17.70
▼ KWD 2.20 (-11.06%)
القيمة السوقية: 32.76B
مُدرج أيضًا باسم DSNKY OTC
نطاق اليوم
KWD 17.70 KWD 18.30
نطاق 52 أسبوعًا
KWD 16.81 KWD 29.15
حجم التداول
379
متوسط 50 يوم / 200 يوم
KWD 19.37 / KWD 22.56
الإغلاق السابق
KWD 19.90

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (627 نظير)

المقياس السهم وسيط القطاع
P/E 0.1 0.3
P/B 0.0 2.9
ROE % 17.9 3.7
Net Margin % 15.7 3.8
Rev Growth 5Y % 18.3 10.0
D/E 0.1 0.2

السعر المستهدف للمحللين

لا تتوفر تغطية محللين

تقديرات الأرباح

الفترة تقدير ربحية السهم تقدير الإيرادات المحللون
FY2030 KWD 341.339
KWD 320.763 – KWD 390.497
 3400 B 3
FY2029 KWD 276.958
KWD 260.263 – KWD 316.845
 3000 B 3
FY2028 KWD 228.103
KWD 214.353 – KWD 260.953
 2600 B 4

النقاط الرئيسية

Revenue grew 18.32% annually over 5 years — strong growth
Earnings grew 47.34% over the past year
ROE of 17.86% — decent returns on equity
Net margin of 15.68% shows strong profitability
Debt/Equity of 0.06 — conservative balance sheet
Negative free cash flow of -134.03B

النمو

Revenue Growth (5Y)
18.32%
Revenue (1Y)17.77%
Earnings (1Y)47.34%
FCF Growth (3Y)N/A

الجودة

Return on Equity
17.86%
ROIC14.43%
Net Margin15.68%
Op. Margin17.60%

الأمان

Debt / Equity
0.06
Current Ratio2.53
Interest Coverage28.00

التقييم

P/E Ratio
0.11
P/B Ratio0.02
EV/EBITDA-1.52
Dividend Yield0.02%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 17.77% Revenue Growth (3Y) 21.47%
Earnings Growth (1Y) 47.34% Earnings Growth (3Y) 64.58%
Revenue Growth (5Y) 18.32% Earnings Growth (5Y) 40.47%
Profitability
Revenue (TTM) 1.89T Net Income (TTM) 295.76B
ROE 17.86% ROA 8.56%
Gross Margin 77.96% Operating Margin 17.60%
Net Margin 15.68% Free Cash Flow (TTM) -134.03B
ROIC 14.43% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.06 Current Ratio 2.53
Interest Coverage 28.00 Dividend Yield 0.02%
Valuation
P/E Ratio 0.11 P/B Ratio 0.02
P/S Ratio 0.02 PEG Ratio 0.43
EV/EBITDA -1.52 Dividend Yield 0.02%
Market Cap 32.76B Enterprise Value -505.74B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 1.89T 1.60T 1.28T 1.04T 962.52B
Net Income 295.76B 200.73B 109.19B 66.97B 75.96B
EPS (Diluted) 155.87 104.62 56.91 34.91 39.11
Gross Profit 1.47T 1.19T 914.95B 682.09B 624.23B
Operating Income 331.93B 211.59B 120.58B 73.03B 63.80B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 3.46T 3.46T 2.51T 2.22T 2.09T
Total Liabilities 1.83T 1.77T 1.06T 864.87B 807.03B
Shareholders' Equity 1.62T 1.69T 1.45T 1.35T 1.27T
Total Debt 101.33B 101.71B 192.86B 213.62B 183.83B
Cash & Equivalents 639.84B 647.18B 334.83B 550.18B 294.80B
Current Assets 1.91T 2.17T 1.50T 1.35T 1.27T
Current Liabilities 754.03B 723.40B 530.26B 395.27B 353.57B

درجات الاستراتيجيات

This stock passed the criteria for 3 strategies

Score = fit strength (0–100)
Rank = position among all matches
Growth Price/Sales Ratio Focus (Ken Fisher)
#337 of 618
32
Custom Contrarian Investing (David Dreman)
#618 of 670
5
Value Defensive Investing (Benjamin Graham)
#579 of 709
10

النشاط الأخير

دخل Contrarian Investing (David Dreman)
Mar 25, 2026
دخل Defensive Investing (Benjamin Graham)
Mar 25, 2026
دخل Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026